Literature DB >> 8968554

Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation.

J L Donato1, S Marcondes, E Antunes, M D Nogueira, H B Nader, C P Dietrich, F Rendu, G de Nucci.   

Abstract

1. Proteoglycans provide negatively charged sites on the surface of platelets, leukocytes and endothelial cells. Since chondroitin 4-sulphate is the main proteoglycan present on the platelet surface, the role of this molecule in mediating the activation of human platelets by polylysine was studied. 2. Platelets were desensitized with phorbol 12-myristate 13-acetate (PMA, 10 nM) 5 min before the addition of polylysine to platelet-rich plasma (PRP). Changes in the intracellular Ca2+ concentration were measured in fura2-am (2 microM) loaded platelets and protein phosphorylation was assessed by autoradiography of the electrophoretic profile obtained from [32P]-phosphate labelled platelets. The release of dense granule contents was measured in [14C]-5-hydroxytryptamine loaded platelets and the synthesis of thromboxane (TXA2) was assessed by radioimmunoassay. Surface chondroitin 4-sulphate proteoglycan was degraded by incubating platelets with different concentrations of chondroitinase AC (3 min, 37 degrees C). The amount of chondroitin 4-sulphate remaining in the platelets was then quantified after proteolysis and agarose gel electrophoresis. 3. The addition of PMA to PRP before polylysine inhibited the aggregation by 88 +/- 18% (n = 3). Staurosporine (1 microM, 5 min) prevented the PMA-induced inhibition. Chondroitinase AC (4 pu ml-1 to 400 muu ml-1, 3 min) abolished the polylysine-induced aggregation in PRP but caused only a discrete inhibition of ADP-induced aggregation. The concentration of chrondroitin 4-sulphate in PRP (0.96 +/- 0.2 microgram/10(8) platelets, n = 3) and in washed platelets (WP; 0.35 +/- 0.1 microgram/10(8) platelets, n = 3) was significantly reduced following incubation with chondroitinase AC (PRP = 0.63 +/- 0.1 microgram/10(8) platelets and WP = 0.08 +/- 0.06 microgram/10(8) platelets). 4. Washed platelets had a significantly lower concentration of chondroitin 4-sulphate than platelets in PRP. The addition of polylysine to WP induced a rapid increase in light transmission which was not accompanied by TXA2 synthesis or the release of dense granule contents. This effect was not inhibited by sodium nitroprusside (SNP), iloprost, EDTA or the peptide RGDS. This event was accompanied by the discrete phosphorylation of plekstrin and myosin light chain, which were inhibited by staurosporine (10 microM, 10 min). The hydrolysis of platelet surface chondroitin 4-sulphate strongly reduced the polylysine-induced phosphorylation. 5. Our results indicate that polylysine activates platelets through a specific receptor which could be the proteoglycan chondroitin 4-sulphate present on the platelet membrane.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968554      PMCID: PMC1915828          DOI: 10.1111/j.1476-5381.1996.tb16057.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Anaphylactoid purpura. I. Pathology of the skin and kidney and frequency of streptococcal infection.

Authors:  R L VERNIER; H G WORTHEN; R D PETERSON; E COLLE; R A GOOD
Journal:  Pediatrics       Date:  1961-02       Impact factor: 7.124

Review 2.  Cell-surface glycosaminoglycans.

Authors:  M Höök; L Kjellén; S Johansson
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

3.  Modulation of adenylate cyclase of human platelets by phorbol ester. Impairment of the hormone-sensitive inhibitory pathway.

Authors:  K H Jakobs; S Bauer; Y Watanabe
Journal:  Eur J Biochem       Date:  1985-09-02

4.  Phorbol myristate acetate inhibits thrombin-stimulated Ca2+ mobilization and phosphatidylinositol 4,5-bisphosphate hydrolysis in human platelets.

Authors:  G B Zavoico; S P Halenda; R I Sha'afi; M B Feinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  Phorbol ester induces desensitization of adenylate cyclase and phosphorylation of the beta-adrenergic receptor in turkey erythrocytes.

Authors:  D J Kelleher; J E Pessin; A E Ruoho; G L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  Heparin prophylaxis of Henoch-Schoenlein nephropathy.

Authors:  Z Szelíd; J Bereczky; Z Nagymányai; V Ruszinkó
Journal:  Acta Paediatr Hung       Date:  1986

7.  Human platelet cationic proteins bind to rat glomeruli, induce loss of anionic charges and increase glomerular permeability.

Authors:  C Tetta; R Coda; G Camussi
Journal:  Agents Actions       Date:  1985-03

8.  Mass changes in myoinositol trisphosphate in human platelets stimulated by thrombin. Inhibitory effects of phorbol ester.

Authors:  S E Rittenhouse; J P Sasson
Journal:  J Biol Chem       Date:  1985-07-25       Impact factor: 5.157

9.  Phorbol esters promote alpha 1-adrenergic receptor phosphorylation and receptor uncoupling from inositol phospholipid metabolism.

Authors:  L M Leeb-Lundberg; S Cotecchia; J W Lomasney; J F DeBernardis; R J Lefkowitz; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  Differentiated microdomains on the luminal surface of the capillary endothelium. II. Partial characterization of their anionic sites.

Authors:  M Simionescu; N Simionescu; J E Silbert; G E Palade
Journal:  J Cell Biol       Date:  1981-09       Impact factor: 10.539

View more
  2 in total

1.  Histones induce rapid and profound thrombocytopenia in mice.

Authors:  Tobias A Fuchs; Ashish A Bhandari; Denisa D Wagner
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

2.  Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.

Authors:  Camila B Mendes-Silverio; Luiz O S Leiria; Rafael P Morganti; Gabriel F Anhê; Sisi Marcondes; Fabíola Z Mónica; Gilberto De Nucci; Edson Antunes
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.